semaglutide and dialysis Add-On, Not Replacement: Semaglutide's Role in Chronic Kidney Disease Management FDA approves Novo Nordisk's Ozempic

The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges

Obesity, commonly present in individuals with type 2 diabetes, independently increases venous thromboembolism risk through mechanical factors, chronic inflammation, and altered coagulation profiles

More importantly, octreotide was approved only for maintenance therapy in patients already stabilized on injectable octreotidea deliberately restricted indication that acknowledges the limitations of oral delivery

Eli Lilly had made early attempts to modify the fatty acid side chain of GLP-1, but did not make a mark in the field